• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Five forces summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Type o Market segments o Comparison by Type o Second-generation ALK inhibitors - Market size and forecast 2019-2024 o First-generation ALK inhibitors - Market size and forecast 2019-2024 o Third-generation ALK inhibitors - Market size and forecast 2019-2024 o Market opportunity by Type • Customer landscape • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o Asia - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography o Volume drivers - Demand led growth o Volume drivers – External factors o Market challenges o Market trends • Vendor Landscape o Overview o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o AstraZeneca Plc o Betta Pharmaceuticals Co. Ltd. o Bio-Techne Corp. o F. Hoffmann-La Roche Ltd. o GlaxoSmithKline Plc o Merck KGaA o Novartis AG o Pfizer Inc. o Takeda Pharmaceutical Co. Ltd. o Turning Point Therapeutics Inc. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibit • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2019 - 2024 ($ million) • 13: Global market: Year-over-year growth 2019 - 2024 (%) • 14: Five forces analysis 2019 & 2024 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2019 • 21: Type - Market share 2019-2024 (%) • 22: Comparison by Type • 23: Second-generation ALK inhibitors - Market size and forecast 2019-2024 ($ million) • 24: Second-generation ALK inhibitors - Year-over-year growth 2019-2024 (%) • 25: First-generation ALK inhibitors - Market size and forecast 2019-2024 ($ million) • 26: First-generation ALK inhibitors - Year-over-year growth 2019-2024 (%) • 27: Third-generation ALK inhibitors - Market size and forecast 2019-2024 ($ million) • 28: Third-generation ALK inhibitors - Year-over-year growth 2019-2024 (%) • 29: Market opportunity by Type • 30: Customer landscape • 31: Market share by geography 2019-2024 (%) • 32: Geographic comparison • 33: North America - Market size and forecast 2019-2024 ($ million) • 34: North America - Year-over-year growth 2019-2024 (%) • 35: Europe - Market size and forecast 2019-2024 ($ million) • 36: Europe - Year-over-year growth 2019-2024 (%) • 37: Asia - Market size and forecast 2019-2024 ($ million) • 38: Asia - Year-over-year growth 2019-2024 (%) • 39: ROW - Market size and forecast 2019-2024 ($ million) • 40: ROW - Year-over-year growth 2019-2024 (%) • 41: Key leading countries • 42: Market opportunity by geography ($ million) • 43: Impact of drivers and challenges • 44: Vendor landscape • 45: Landscape disruption • 46: Industry risks • 47: Vendors covered • 48: Market positioning of vendors • 49: AstraZeneca Plc - Overview • 50: AstraZeneca Plc - Product and service • 51: AstraZeneca Plc - Key offerings • 52: AstraZeneca Plc - Key customers • 53: AstraZeneca Plc - Segment focus • 54: Betta Pharmaceuticals Co. Ltd. - Overview • 55: Betta Pharmaceuticals Co. Ltd. - Product and service • 56: Betta Pharmaceuticals Co. Ltd. - Key offerings • 57: Betta Pharmaceuticals Co. Ltd. - Key customers • 58: Betta Pharmaceuticals Co. Ltd. - Segment focus • 59: Bio-Techne Corp. - Overview • 60: Bio-Techne Corp. - Business segments • 61: Bio-Techne Corp. - Key offerings • 62: Bio-Techne Corp. - Key customers • 63: Bio-Techne Corp. - Segment focus • 64: F. Hoffmann-La Roche Ltd. - Overview • 65: F. Hoffmann-La Roche Ltd. - Business segments • 66: F. Hoffmann-La Roche Ltd. - Key offerings • 67: F. Hoffmann-La Roche Ltd. - Key customers • 68: F. Hoffmann-La Roche Ltd. - Segment focus • 69: GlaxoSmithKline Plc - Overview • 70: GlaxoSmithKline Plc - Business segments • 71: GlaxoSmithKline Plc - Key offerings • 72: GlaxoSmithKline Plc - Key customers • 73: GlaxoSmithKline Plc - Segment focus • 74: Merck KGaA - Overview • 75: Merck KGaA - Business segments • 76: Merck KGaA - Key offerings • 77: Merck KGaA - Key customers • 78: Merck KGaA - Segment focus • 79: Novartis AG - Overview • 80: Novartis AG - Business segments • 81: Novartis AG - Key offerings • 82: Novartis AG - Key customers • 83: Novartis AG - Segment focus • 84: Pfizer Inc. - Overview • 85: Pfizer Inc. - Business segments • 86: Pfizer Inc. - Key offerings • 87: Pfizer Inc. - Key customers • 88: Pfizer Inc. - Segment focus • 89: Takeda Pharmaceutical Co. Ltd. - Overview • 90: Takeda Pharmaceutical Co. Ltd. - Product and service • 91: Takeda Pharmaceutical Co. Ltd. - Key offerings • 92: Takeda Pharmaceutical Co. Ltd. - Key customers • 93: Takeda Pharmaceutical Co. Ltd. - Segment focus • 94: Turning Point Therapeutics Inc. - Overview • 95: Turning Point Therapeutics Inc. - Product and service • 96: Turning Point Therapeutics Inc. - Key offerings • 97: Turning Point Therapeutics Inc. - Key customers • 98: Turning Point Therapeutics Inc. - Segment focus • 99: Currency conversion rates for US$ • 100: Research Methodology • 101: Validation techniques employed for market sizing • 102: Information sources • 103: List of abbreviations

AstraZeneca Plc, Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Turning Point Therapeutics Inc.